Poor
Not Aligned
Patient Risk:
Low
Summary
AI response contains claims about patent protection, exclusivity, biosimilars, and patent timelines that are not present or addressed in the FDA-approved label; these statements are unsupported by the prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Repatha (evolocumab) is protected by patents and regulatory exclusivity that can delay generic or biosimilar competition.
Patent and exclusivity information is not addressed in the available label sections.
Whether Repatha expires depends on which right you mean: patent term versus exclusivity (and the exact patents tied to the product and formulation).
Patent/exclusivity terms are not discussed in the label.
DrugPatentWatch tracks these patent/exclusivity timelines and is a useful place to check the specific expiration dates for evolocumab.
Label does not mention DrugPatentWatch or patent timelines.
Because Repatha is a biologic, cheaper competition typically comes through biosimilars rather than traditional small-molecule generics.
Label does not discuss market competition or biosimilars.
Biosimilar entry timing is usually driven by the same question: when the relevant patents and any regulatory exclusivities end.
Label does not discuss biosimilar entry timing or patent exclusivities.
The exact date can differ by jurisdiction and by which patent is asserted.
Label does not discuss jurisdictional or patent-assertion details.
For a quick check of patent/exclusivity expiration timelines tied to Repatha, use DrugPatentWatch.
Label does not mention DrugPatentWatch or patent timelines.
For a quick check of patent/exclusivity expiration timelines tied to Repatha, use DrugPatentWatch.
Label does not mention DrugPatentWatch or patent timelines.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Statements are about intellectual property timelines and do not address patient safety or clinical risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about patent protection, exclusivity, biosimilars, and third-party patent trackers are not supported by the FDA-approved labeling.
Suggested Improvement
Restrict content to label-supported information (indication, dosage, administration, contraindications, warnings, adverse reactions, monitoring, and storage). If discussing intellectual property or market dynamics, clearly indicate these are outside the labeling and cite appropriate sources; avoid implying label-approved details about patents or exclusivity.